Company Seeks Permission to Import Mystery Controlled Substances
Published Date: 11/26/2025
Notice
Summary
Noramco wants to become an official importer of some controlled substances like marijuana and methadone. If you’re a registered manufacturer or interested party, you have until December 26, 2025, to share your thoughts or ask for a hearing. This move could affect companies dealing with these drugs and might impact how these substances enter the U.S.
Analyzed Economic Effects
6 provisions identified: 2 benefits, 2 costs, 2 mixed.
Noramco applied to import listed controlled substances
On September 22, 2025, Noramco applied to be registered as an importer for multiple controlled substances, including Gamma Hydroxybutyric Acid (code 2010, Schedule I), Marihuana (7360, Schedule I), Tetrahydrocannabinols (7370, Schedule I), Methadone-Intermediate (9254, Schedule II), and various opium codes (e.g., 9600–9670, Schedule II). This notice publicly announces that application and identifies the exact drug codes the company seeks to import.
Planned import of Poppy Straw Concentrate (9670)
Noramco plans to import Poppy Straw Concentrate (drug code 9670) to bulk manufacture other controlled substances for distribution to its customers. This planned import is specifically for bulk manufacturing use and distribution to Noramco's customers.
Planned import of Tapentadol intermediate (9780)
Noramco plans to import an intermediate form of Tapentadol (drug code 9780) to bulk manufacture Tapentadol for distribution to its customers. The application states the intermediate will be used for bulk manufacture rather than finished product importation.
Synthetic CBD and THC import limits for marijuana codes
For drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), Noramco's application says it plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. The notice also states that no other activities for these drug codes are authorized under this registration.
Finished dosage forms not authorized for import
The notice states that authorization will not extend to the import of Food and Drug Administration (FDA) approved or non-approved finished dosage forms for commercial sale. The registration is limited to activities consistent with 21 U.S.C. 952(a)(2).
Comment and hearing request deadline: Dec 26, 2025
Registered bulk manufacturers of the affected classes and other applicants may submit electronic comments, objections, or a written request for a hearing on Noramco's application on or before December 26, 2025. Comments must be submitted via regulations.gov; hearing requests have specified mailing addresses in Springfield, VA.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-21190, Bulk Manufacturer of Controlled Substances Application: National Center for Natural Products Research
The National Center for Natural Products Research wants to officially make large amounts of marijuana and related substances for research and product development. If you’re a current manufacturer or interested party, you can share your thoughts or ask for a hearing by January 26, 2026. This move could boost scientific studies and product testing, with no immediate cost changes announced.
Next: 2025-21192, Bulk Manufacturer of Controlled Substances Application: Noramco
Noramco wants to become a big-time maker of certain controlled drugs, including marijuana and some painkillers. People and companies already registered can share their thoughts or ask for a hearing by January 26, 2026. This move could affect drug supply chains and involves careful government review, but no direct costs are mentioned yet.